Directori

ALEJANDRO HERNÁNDEZ MARTINEZ

Oncología de Precisión de Girona

Firma

ALEJANDRO HERNÁNDEZ-MARTINEZ

Posición

Investigador/a Pre-doctoral – R1

Investigadores/as Pre-doctorales – R1

Projectes

Oncología de Precisión de Girona

Estudi "Organ specific biomarkers and therapies to improve the management of brain metastasis".

Codi oficial: La Marató 201906-30 Data inicio:30/09/2020 Data fi: 31/01/2024 Investigador/a principal: JOAQUIM BOSCH BARRERA Organisme finançador: FUNDACIO LA MARATO TV3 Ajuda: 109,562.50 €

Publicacions

Oncología de Precisión de Girona , Metabolismo y Cáncer

Teixidor E, Sais E, Vásquez CA, Carbajal W, Hernández A, Sánchez G, Izquierdo A, Verdura S, Menéndez JA, Bosch-Barrera J

Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.

Oncotarget, 2023, 14, 668-668 dx.doi.org/10.18632/oncotarget.28471

Metabolismo y Cáncer , Oncología de Precisión de Girona

Monteiro C, Miarka L, Perea-García M, Priego N, García-Gómez P, Álvaro-Espinosa L, de Pablos-Aragoneses A, Yebra N, Retana D, Baena P, Fustero-Torre C, Graña-Castro O, Troulé K, Caleiras E, Tezanos P, Muela P, Cintado E, Trejo JL, Sepúlveda JM, González-León P, Jiménez-Roldán L, Moreno LM, Esteban O, Pérez-Núñez Á, Hernández-Lain A, Mazarico Gallego J, Ferrer I, Suárez R, Garrido-Martín EM, Paz-Ares L, Dalmasso C, Cohen-Jonathan Moyal E, Siegfried A, Hegarty A, Keelan S, Varešlija D, Young LS, Mohme M, Goy Y, Wikman H, Fernández-Alén J, Blasco G, Alcázar L, Cabañuz C, Grivennikov SI, Ianus A, Shemesh N, Faria CC, Lee R, Lorigan P, Le Rhun E, Weller M, Soffietti R, Bertero L, Ricardi U, Bosch-Barrera J, Sais E, Teixidor E, Hernández-Martínez A, Calvo A, Aristu J, Martin SM, Gonzalez A, Adler O, Erez N, RENACER, Valiente M

Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

NATURE MEDICINE, 2022, 28, 752-765 dx.doi.org/10.1038/s41591-022-01749-8

Metabolismo y Cáncer , Epidemiología descriptiva, genética y prevención del cáncer , Oncología de Precisión de Girona

Bosch-Barrera J, Verdura S, Ruffinelli JC, Carcereny E, Sais E, Cuyàs E, Palmero R, Lopez-Bonet E, Hernández-Martínez A, Oliveras G, Buxó M, Izquierdo A, Morán T, Nadal E, Menendez JA

Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer

Cancers, 2021, 13 dx.doi.org/10.3390/cancers13164168

Oncología de Precisión de Girona

Palomeras S, Diaz-Lagares Á, Viñas G, Setien F, Ferreira HJ, Oliveras G, Crujeiras AB, Hernández A, Lum DH, Welm AL, Esteller M, Puig T

Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer

BREAST CANCER RESEARCH, 2019, 21, 79-79 dx.doi.org/10.1186/s13058-019-1160-x

Metabolismo y Cáncer , Oncología de Precisión de Girona

López Brunsó M, Toro Blanch C, Sais Girona E, Roa García D, Hernández Martínez A, Izquierdo Font A, Guerra Prió S, Mas Pueyo HG, Bosch-Barrera J

Probable drug-drug interaction between erlotinib and amiodarone causes severe neurotoxicity in a patient with advanced lung cancer

ANTI-CANCER DRUGS, 2018, 29, 380-383 dx.doi.org/10.1097/CAD.0000000000000600

Formulari de contacte

Patronato

Centro de

Directori

ALEJANDRO HERNÁNDEZ MARTINEZ

Projectes

Publicacions

Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.

Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer

Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer

Probable drug-drug interaction between erlotinib and amiodarone causes severe neurotoxicity in a patient with advanced lung cancer

Formulari de contacte

Conoce el IDIBGI!